NCT04998487View on ClinicalTrials.gov

A Single-Dose Study of LY3471851 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

July 6, 2022

Study Completion Date

July 6, 2022

Conditions
Healthy
Interventions
DRUG

LY3471851

Administered SC.

Trial Locations (1)

32117

LabCorp CRU, Inc., Daytona Beach

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Nektar Therapeutics

INDUSTRY